Crinetics Pharmaceuticals (CRNX) Share-based Compensation (2017 - 2026)

Crinetics Pharmaceuticals' Share-based Compensation history runs 10 years deep, the most recent figure standing at $29.7 million for Q1 2026.

• On a quarterly basis, Share-based Compensation rose 44.94% year-over-year to $29.7 million in Q1 2026; TTM through Mar 2026 was $100.2 million, a 31.17% increase from a year earlier, with the FY2025 full-year figure at $91.0 million, up 31.18% from the prior year.
• Share-based Compensation improved to $29.7 million in Q1 2026 per CRNX's latest filing, from $21.7 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $29.7 million in Q1 2026 and bottomed at $5.8 million in Q1 2022.
• The 5-year median for Share-based Compensation is $13.5 million (2024), against an average of $15.3 million.
• Across the five-year window, Share-based Compensation soared 86.14% in 2024 and increased 15.26% in 2025, its largest moves.
• Year by year, Share-based Compensation stood at $7.9 million in 2022, then surged by 46.16% to $11.6 million in 2023, then jumped by 62.22% to $18.8 million in 2024, then advanced by 15.26% to $21.7 million in 2025, then soared by 36.65% to $29.7 million in 2026.
• Per Business Quant, the three latest CRNX Share-based Compensation figures stand at $29.7 million (Q1 2026), $21.7 million (Q4 2025), and $22.7 million (Q3 2025).